Market Place
Sourcing Support
Neurelis Enters $208M Agreement to Monetize Intravail Royalties
14 Nov 2024 //
PR NEWSWIRE
Neurelis Shares Valtoco® Study Design for Ages 2-5 at CNS Meeting
11 Nov 2024 //
PR NEWSWIRE
Neurelis AAN Posters On Epilepsy, Movement Disorders
11 Apr 2024 //
PR NEWSWIRE
Neurelis Announces Presentations At The American Epilepsy Society Annual Meeting
01 Dec 2023 //
PR NEWSWIRE
Neurelis Secures New Orange Book Listed U.S. Patent For Valtoco
27 Nov 2023 //
PR NEWSWIRE
Neurelis to Participate in the 6th Annual Evercore ISI HealthCONx Conference
16 Nov 2023 //
PR NEWSWIRE
Neurelis To Participate In 11Th Annual Sofie`S Journey Epilepsy Awareness Day
30 Oct 2023 //
PR NEWSWIRE
Neurelis To Present Analyses Of Valtoco Civ at the Annual Meeting
04 Oct 2023 //
PR NEWSWIRE
Neurelis To Present Analyses Of Valtoco Civ Highlighting Effects
31 Aug 2023 //
PR NEWSWIRE
Neurelis Announces Four Poster Presentations At The 75Th Meeting
25 Apr 2023 //
PR NEWSWIRE
NEURELIS ANNOUNCES FIRST HEALTHY SUBJECTS DOSED IN STUDY OF NRL-1049
24 Mar 2023 //
PR NEWSWIRE
Neurelis Announces Filing of Its Investigational NDA For Nrl-1049
09 Jan 2023 //
PR NEWSWIRE
FDA Accepted Intranasal Epinephrine NDA of Ars Pharmaceuticals
09 Dec 2022 //
BIONJ
Neurelis, Inc. to Participate in 5th Annual Evercore ISI HealthCONx Conference
28 Nov 2022 //
PRNEWSWIRE
Neurelis Supports Sofie`s Journey Epilepsy Awareness Day
31 Oct 2022 //
PRNEWSWIRE
Neurelis Presents Novel, Investigational Analysis Of VALTOCO
13 Oct 2022 //
BIOSPACE
Neurelis Announces Presentation Of Analysis TimeBetween Seizure Clusters VALTOCO
12 Oct 2022 //
PRNEWSWIRE
Neurelis to Present Analysis of Time Between Seizure Clusters With Valtoco Civ
12 Oct 2022 //
PRNEWSWIRE
Study Published In Epilepsia Shows Intervals Between Seizure Clusters Treated
07 Sep 2022 //
PRNEWSWIRE
NEURELIS, INC., NAMED TO LIST OF BEST PLACES TO WORK IN SoCAL 2022
18 Aug 2022 //
PRNEWSWIRE
Neurelis Study Published In Epilepsia
09 Jun 2022 //
PRNEWSWIRE
Neurelis Presented Clinical Data Supporting Seizure Cluster Interval Analysis
07 Jun 2022 //
PRNEWSWIRE
Neurelis To Highlight Valtoco CIV Development Program Updates
31 May 2022 //
PRNEWSWIRE
Data From Novel, Exploratory Analysis Of Intermittent Valtoco CIV Use
05 May 2022 //
PRNEWSWIRE
Neurelis Expands Intellectual Property Estate For VALTOCO
26 Apr 2022 //
PRNEWSWIRE
Neurelis Announces Three Poster Presentations At The 2022 AAN
04 Apr 2022 //
PRNEWSWIRE
NEURELIS SIGNS EXCLUSIVE LICENSING AGREEMENT WITH ACULYS PHARMA FOR VALTOCO
25 Jan 2022 //
PRNEWSWIRE
Neurelis Announces 16 Poster Presentations at the Annual Meeting
02 Dec 2021 //
PRNEWSWIRE
Neurelis Appoints CFO, Expands Leadership Team and Board of Directors
18 Oct 2021 //
PRNEWSWIRE
Neurelis Announces Acquisition Of Rights To Portfolio Of NCE Compounds
21 Jun 2021 //
PRNEWSWIRE
Neurelis Announces Five Poster Presentations for the Annual Meeting
19 Apr 2021 //
PRNEWSWIRE
Neurelis Announces Two Poster Presentations for the Annual Meeting
13 Apr 2021 //
PRNESWIRE
Neurelis Announces Close Of $114 Million Series D Financing Round
10 Mar 2021 //
PRNEWSWIRE
Neurelis Announces 12 Poster Presentations For The Annual Meeting
04 Dec 2020 //
PRNEWSWIRE
Neurelis Completes Pre-IND Meeting With FDA to Establish DevP for NRL-4
23 Nov 2020 //
BIOSPACE
Neurelis Completes Pre-IND Meeting With FDA to DevP Program for NRL-4
23 Nov 2020 //
PRNEWSWIRE
Neurelis Announces FDA Approval Of Extended Expiration Dating For VALTOCO®
19 Oct 2020 //
PRNEWSWIRE
Neurelis Announces Four Poster Presentations For The Joint Meeting
16 Oct 2020 //
PRNEWSWIRE
Neurelis Announces Four Poster Presentations For The Joint Meeting
15 Oct 2020 //
PRNEWSWIRE
